Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of  U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.

According to Reuters, the deal will help Ono expand its oncology portfolio and presence in the United States and Europe.

Deciphera's oral drug Qinlock, which treats a type of gastrointestinal cancer, received the U.S. Food and Drug Administration's full approval in 2020. The company also plans to seek a nod for vimseltinib, its experimental medicine to treat tenosynovial giant cell tumour, a type of tumour found in some joints, Reuters added.

The Greenberg Traurig team was co-led by shareholders Chia-Feng Lu and Michael D. Helsel, while the Goodwin team was helmed by global M&A head Stuart Cable and partners Richard Hoffman, Lisa Haddad, and James Ding.



Related Articles

A&O Shearman advises Allianz on $1.6 bln Singapore insurance deal

by Nimitt Dixit |

A&O Shearman has advised German insurer Allianz on the acquisition of a 51 percent stake in Singapore's Income Insurance for S$2.2 billion ($1.6 billion), the latest major deal in Singapore’s buzzing insurance sector.

INDIA REPORT: Merger Momentum

by Nimitt Dixit |

Despite global uncertainties, India's M&A landscape remains robust, with domestic deals driving growth and diverse sectors attracting investments. Experts predict a positive outlook for H2 2024, bolstered by policy continuity and abundant dry powder.

Simpson Thacher, Nishimura act on Blackstone’s $2.17 bln Japan pharma sale

by Nimitt Dixit |

Japanese law firm Nishimura & Asahi has represented private equity group MBK Partners on its acquisition of drugmaker Alinamin Pharmaceuticals for 350 billion yen ($2.17 billion) from PE giant Blackstone, which was advised by its longstanding firm Simpson Thacher & Bartlett.